The FDA declined to approve one of biotech’s most closely watched cancer drugs
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
Original Source
Read the full article at Marketwatch →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.